Kyverna Therapeutics shares surged after the company reported positive results from its registrational Phase 2 KYSA-8 trial of mivocabtagene autoleucel in stiff person syndrome. A single infusion delivered sustained improvements across primary and secondary endpoints, boosting optimism for a potential treatment in the rare autoimmune disease.